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ABSTRACT Traditionally, the emergence of coronaviruses (CoVs) has been attrib-
uted to a gain in receptor binding in a new host. Our previous work with severe
acute respiratory syndrome (SARS)-like viruses argued that bats already harbor CoVs
with the ability to infect humans without adaptation. These results suggested that
additional barriers limit the emergence of zoonotic CoV. In this work, we describe
overcoming host restriction of two Middle East respiratory syndrome (MERS)-like bat
CoVs using exogenous protease treatment. We found that the spike protein of
PDF2180-CoV, a MERS-like virus found in a Ugandan bat, could mediate infection of
Vero and human cells in the presence of exogenous trypsin. We subsequently show
that the bat virus spike can mediate the infection of human gut cells but is unable
to infect human lung cells. Using receptor-blocking antibodies, we show that infec-
tion with the PDF2180 spike does not require MERS-CoV receptor DPP4 and antibodies
developed against the MERS spike receptor-binding domain and S2 portion are ineffec-
tive in neutralizing the PDF2180 chimera. Finally, we found that the addition of exoge-
nous trypsin also rescues HKU5-CoV, a second bat group 2c CoV. Together, these results
indicate that proteolytic cleavage of the spike, not receptor binding, is the primary infec-
tion barrier for these two group 2c CoVs. Coupled with receptor binding, proteolytic ac-
tivation offers a new parameter to evaluate the emergence potential of bat CoVs and of-
fers a means to recover previously unrecoverable zoonotic CoV strains.
IMPORTANCE Overall, our studies demonstrate that proteolytic cleavage is the pri-
mary barrier to infection for a subset of zoonotic coronaviruses. Moving forward, the
results argue that both receptor binding and proteolytic cleavage of the spike are
critical factors that must be considered for evaluating the emergence potential and
risk posed by zoonotic coronaviruses. In addition, the findings also offer a novel
means to recover previously uncultivable zoonotic coronavirus strains and argue
that other tissues, including the digestive tract, could be a site for future coronavirus
emergence events in humans.
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Since the beginning of the 21st century, public health infrastructures have beenrequired to periodically respond to new and reemerging zoonotic viral diseases,
including influenza, Ebola, and Zika virus outbreaks (1). Severe acute respiratory
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syndrome coronavirus (SARS-CoV), the first major outbreak of the century, highlighted 
the global impact of a newly emerging virus in the context of expanding development, 
increased globalization, and poor public health infrastructures (2–4). A decade later, the 
emergence and continued outbreaks of the Middle East respiratory syndrome corona-
virus (MERS-CoV) further illustrate the ongoing threat posed by circulating zoonotic 
viruses (5). Together, the outbreaks of the early part of this century argue that 
continued preparations and vigilance are needed to maintain global public health.
Despite their spontaneous emergence, several research approaches to rapidly re-
spond and even predict outbreak strains already exist. During the MERS-CoV outbreak, 
our group and others were able to leverage reagents generated against related group 
2C coronaviruses, namely, HKU4- and HKU5-CoV (6, 7). These reagents, created inde-
pendent of viable virus replication, provided valuable insights and models for testing 
serologic responses during the early stages of the MERS-CoV outbreak. Similarly, 
reverse genetics systems permitted the exploration of zoonotic coronaviruses (8); using 
the known SARS spike/ACE2 receptor interaction, chimeric viruses containing the 
backbones of bat CoVs were generated to evaluate the efficacy of both vaccines and 
therapeutics (9–12). The inverse approach placed the zoonotic spike proteins in the 
context of the epidemic SARS-CoV backbone (13, 14). These studies provided insight 
into potential threats circulating in bats as well as the efficacy of current therapeutic 
treatments (15). While far from comprehensive, the results indicated that these ap-
proaches, reagents, and predictions may prove useful in preparations for future CoV 
outbreaks.
In this study, we extend the examination of zoonotic viruses to a novel MERS-like 
CoV strain isolated from a Ugandan bat, namely, PDF-2180 CoV (MERS-Uganda). Our 
initial attempt to cultivate a chimeric MERS-CoV containing the Ugandan MERS-like 
spike produced viral subgenomic transcripts but failed to result in infectious virus after 
electroporation (16). However, in the current study, we demonstrate that exogenous 
trypsin treatment produced high-titer virus capable of plaque formation and continued 
replication. These results are consistent with the recovery of enteric CoVs like porcine 
epidemic diarrhea virus (17) but have not previously been described as a major barrier 
for bat-derived CoVs. The chimeric Ugandan MERS-like spike virus could replicate 
efficiently in both Vero and Huh7 cells in the context of trypsin-containing media but 
failed to produce infection of either continuous or primary human respiratory cell 
cultures. Importantly, the MERS-Uganda chimeric virus successfully infected cells of the 
human digestive tract, potentially identifying another route for cross-species transmis-
sion and emergence. Notably, blockade of human DPP4, the receptor for MERS-CoV, 
had no significant impact on replication of the chimeric MERS-Uganda virus, suggesting 
the use of an alternative receptor. Similarly, the addition of trypsin also rescued 
replication of full-length HKU5-CoV, a related group 2C bat CoV, and showed no 
replication defect during DPP4 blockade. Together, the results indicate that proteolytic 
activation of the spike protein is a potent constraint to infection for zoonotic CoVs and 
expand the correlates for CoV emergence beyond receptor binding alone.
RESULTS
Utilizing the MERS-CoV infectious clone (19), we previously attempted to evaluate 
the potential of PDF-2180 CoV to emerge from zoonotic populations. Replacing the 
wild-type MERS-CoV spike with the PDF-2180 spike produced a virus capable of 
generating viral transcripts in vitro but not sustained replication (16). These results 
suggested that the significant amino acid differences observed within the receptor-
binding domain precluded infection of Vero cells. However, amino acid changes were 
not confined only to the receptor-binding domain (RBD); highlighting changes be-
tween the Uganda spike on the MERS-CoV trimer revealed significant differences 
throughout the S1 region of spike (Fig. 1A and B). While the S2 remained highly 
conserved (Fig. 1C), changes in the C- and N-terminal domains of S1, in addition to the 
RBD, may also influence entry and infection compatibility. Notably, recent reports had
FIG 1 Exogenous trypsin rescues MERS-Uganda spike replication. (A and B) Structure of the MERS-CoV spike trimer in complex with the
receptor human DPP4 (red) from the side (A) and top (B). Consensus amino acids are outlined for the S1 (gray) and S2 (black) domains,
with PDF-2180 differences noted in magenta. (C) Spike protein sequences of the indicated viruses were aligned according to the bounds
of total spike, S1, S2, and receptor-binding domain (RBD). Sequence identities were extracted from the alignments, and a heatmap of
sequence identity was constructed using EvolView (www.evolgenius.info/evolview) with MERS-CoV as the reference sequence. (D)
MERS-Uganda chimera stocks were grown in the presence or absence of trypsin and were quantitated by plaque assay with a
trypsin-containing overlay (n  2). (E) Protein expression of MERS-Uganda spike (S) and actin 24 and 48 hours postinfection of Vero cells
in the presence of increasing amounts of trypsin (none, 0.25 g/ml, and 0.5 g/ml) in the media.
also indicated differential protease cleavage of wild-type MERS-CoV based on cell types, 
suggesting that spike processing influences docking and entry of pseudotyped virus 
(20). To explore if spike cleavage impaired infectivity, we evaluated MERS-Uganda virus 
replication in the presence of trypsin-containing media. The addition of trypsin to the 
chimeric virus resulted in cytopathic effect, fusion of the Vero monolayer, formation of 
plaques under a trypsin-containing overlay, and collection of high-titer infectious virus 
stock (Fig. 1D). Utilizing the trypsin-treated stock, we subsequently examined the 
MERS-Uganda spike by Western blotting, finding that increasing amounts of trypsin 
produced more robust spike expression and cleavage (Fig. 1E). Together, these data 
indicate that the PDF-2180 spike can mediate infection of Vero cells in a trypsin-
dependent manner.
The requirement for trypsin complicated our studies due to cell toxicity; to over-
come this issue, we utilized both trypsin-adapted Vero cells and a MERS-Uganda 
chimera encoding RFP in place of open reading frame 5 (ORF5), similar to a previously 
generated MERS-CoV reporter virus (19). Following MERS-Uganda infection, cultures 
with trypsin-containing medium showed evidence for replication of viral genomic RNA 
(Fig. 2A). Similarly, the nucleocapsid protein was observed only in the presence of 
exogenous trypsin following infection with the MERS-Uganda chimera (Fig. 2B). Nota-
bly, wild-type MERS-CoV expressing RFP was also augmented in the presence of trypsin 
with increased genomic RNA and nucleocapsid protein relative to no trypsin control 
(Fig. 2A and B). Examination of RFP signal confirmed these RNA and protein results (Fig. 
2C), as RFP was only observed in MERS-Uganda chimeric infection in the presence of
FIG 2 Trypsin treatment augments MERS and Uganda spike-mediated infection. (A) Trypsin-resistant Vero cells
were infected with MERS-CoV (black) or MERS-Uganda chimera (magenta) and were monitored for expression of
genomic RNA in the presence or absence of trypsin (n  3 for each time point). (B) Protein expression of MERS-CoV
nucleocapsid (N) and actin 18 hours postinfection of Vero cells in the presence or absence of trypsin in the media.
(C) RFP expression microscopy in Vero cells infected with MERS-CoV, MERS-Uganda spike chimera, or mock in the
presence or absence of trypsin.
trypsin. Similarly, viral RNA, RFP expression, and N protein expression were more robust 
in trypsin-treated cells following MERS-CoV infection. Together, these data indicate that 
both the PDF-2180 and MERS-CoV spike have augmented infection of Vero cells in the 
presence of trypsin.
MERS-Uganda spike replicates in human cells. Having demonstrated infection 
and replication, we next sought to determine the capacity of MERS-Uganda chimeric 
virus to grow in human cells. Previously, MERS-CoV had been shown to replicate 
efficiently in Huh7 cells (21). In the Huh7 liver cell line, infection with MERS-Uganda RFP 
chimeric virus resulted in RFP-positive cells and cell fusion (Fig. 3A). In contrast, while 
a few RFP-positive cells were observed in the non-trypsin-treated group, neither 
expanding RFP expression nor cytopathic effect were seen in the absence of trypsin. 
Our observation may have been the result of residual trypsin activity from the undiluted 
virus stock, resulting in low-level infection. Exploring further, N protein analysis by 
Western blotting indicated that the PDF-2180 spike chimera could produce significant 
viral proteins in the presence of trypsin (Fig. 3B); only low levels of protein were 
observed in the control-treated infection. While replication of the MERS-Uganda chi-
mera was not equivalent to that of wild-type MERS-CoV, the results clearly demonstrate 
the capacity of the PDF-2180 spike to mediate infection of human cells in the presence 
of trypsin.
We next examined the capacity of the MERS-Uganda spike to infect human respi-
ratory cells, the primary targets of SARS-CoV, MERS-CoV, and other common cold-
causing human CoVs. Using Calu3 cells, a human lung epithelial cell line, we observed 
robust replication of wild-type MERS-CoV based on RFP expression, consistent with 
previous studies (19). However, no evidence of infection was noted in MERS-Uganda-
infected Calu3 cells in the presence or absence of trypsin. We subsequently explored 
infection of primary human airway epithelial (HAE) cultures. Grown on an air-liquid 
interface, HAE cultures have a propensity to facilitate improved infections of several 
human CoVs and may be more permissive for infection with the PDF-2180 spike 
chimera (22). To infect, PDF-2180 chimeric virus grown in the presence of trypsin was 
inoculated onto the apical surface of the HAE culture; cultures were subsequently
FIG 3 MERS-Uganda spike chimera replicates in human cells. (A and B) Huh7 cells were infected with MERS-CoV or MERS-Uganda chimeric viruses, showing
microscopy images of cell monolayer and RFP expression with and without trypsin treatment (A) and N protein expression following infection of Huh7 cells
in the presence or absence of trypsin (B). (C and D) Primary HAE cultures were infected with MERS-CoV or MERS-Uganda chimera, showing RFP expression (C)
and genomic viral RNA following infection (D) (n  3 for 8 and 24 hours postinfection [hpi]). (E and F) Caco-2 cells were infected with MERS-CoV or MERS-Uganda
chimeric viruses expressing RFP, showing microscopy images of cell monolayer and RFP expression with and without trypsin treatment (E) and N protein
expression following infection of Caco-2 cells in the presence or absence of trypsin (F).
washed with phosphate-buffered saline (PBS) containing 5 g/ml trypsin at 0, 18, 24, 
and 48 hours postinfection for 10 minutes and then removed. Following infection, no 
evidence of RFP expression was observed even after trypsin washes of the apical 
surface (Fig. 3C). Similarly, RNA expression analysis found no evidence for accumulation 
of viral genomic RNA, indicating no evidence for replication in HAE cultures (Fig. 3D). 
In contrast, wild-type MERS-CoV efficiently infects these HAE cultures, as demonstrated 
by both RFP expression and viral genomic RNA accumulation. Together, the Calu3 and 
HAE results suggest that the PDF-2180 spike is unable to infect respiratory cells in 
humans, even in the presence of exogenous trypsin.
We next evaluated the capacity of the PDF-2180 chimera to infect cells of the 
digestive tract. While uncommon in humans, several animal CoVs have been shown to 
cause severe disease via the enteric pathway (23, 24). In addition, most bat CoV 
sequences, including PDF-2180-CoV, were isolated from bat guano samples, suggesting 
an enteric etiology. Importantly, the presence of trypsin and other soluble host pro-
teases in the digestive tract may facilitate infection with the PDF-2180 spike in humans. 
To test this question, we infected Caco-2 cells, a human epithelial colorectal adeno-
carcinoma cell line, with wild-type MERS-CoV and MERS-Uganda spike chimera in the 
presence or absence of trypsin (Fig. 3E). For MERS-CoV, infection of Caco-2 cells resulted 
in robust infection and spread with or without trypsin in the media. For the MERS-
Uganda chimera, the addition of trypsin facilitated infection with many RFP-positive 
Caco-2 cells; however, infection was not as robust as in the wild-type MERS-CoV 
infection. Examination of N protein by Western blotting indicated that the MERS-
Uganda spike could produce infection in Caco-2 cells but confirmed replication at levels 
lower than that with wild-type MERS-CoV (Fig. 3F). Together, the results indicate that
FIG 4 MERS-Uganda spike does not utilize DPP4 for infection. (A and B) Vero cells were infected with 
MERS-CoV or MERS-Uganda chimeric virus in the presence or absence of trypsin and a blocking antibody 
against human DPP4. (A) Fluorescent microscopy showing RFP expression 24 hours postinfection for 
each treatment group. (B) Western blot of N protein and actin 24 hours postinfection.
human cells, including gut cells, can support infection with the MERS-Uganda chimera 
in the presence of trypsin.
MERS-Uganda spike does not use DPP4 for entry. The absence of infection of 
human respiratory cells coupled with significant changes in the RBD suggested that 
MERS-Uganda does not utilize the MERS-CoV receptor human DPP4 for entry (16). To 
explore this question, we utilized antibodies to block DPP4 in Vero cells to determine 
the effect on MERS-Uganda chimeric virus replication. As expected, the anti-DPP4 
antibody successfully ablated replication of wild-type MERS-CoV in both the presence 
and the absence of trypsin treatment, as measured by both RFP and N protein 
expression (Fig. 4A and B). In contrast, the human DPP4-blocking antibody had no 
impact on infection with the MERS-Uganda chimera virus in the presence of trypsin, 
confirming that the MERS-CoV receptor is not required to mediate infection with the 
PDF-2180 spike. Together, these results indicate that while the MERS-Uganda spike 
infects human cells, it does not require human DPP4 to mediate infection.
FIG 5 Antibodies against MERS-CoV fail to neutralize MERS-Uganda chimera. (A) Structure of the 
MERS-CoV spike trimer with therapeutic antibody LCA60 bound adjacent to the receptor-binding domain 
and the antibody G4 bound to the S2 portion. Consensus amino acids are outlined for the S1 (gray) and 
S2 (black) domains, with PDF-2180 differences noted in magenta. (B and C) Plaque neutralization curves 
for LCA60 (B) and G4 (C) with (solid) and without (dotted) trypsin treatment for MERS-CoV (black) and 
MERS-Uganda chimera (magenta) (n  3 per concentration).
MERS-CoV therapeutics are ineffective against MERS-Uganda spike. Having 
established replication capacity in human cells, we next sought to determine if thera-
peutics developed against the MERS-CoV spike could disrupt infection with the MERS-
Uganda spike chimera. Several monoclonal antibodies have been identified as possible 
therapeutic options for the treatment of MERS-CoV, including LCA60 and G4. We first 
evaluated LCA60, a potent antibody that binds adjacent to the spike RBD of MERS-CoV 
(25). However, the major changes in the RBD region of the MERS-Uganda spike 
predicted a lack of efficacy (Fig. 5A). LCA60 potently neutralized wild-type MERS-CoV 
grown in both the presence and the absence of trypsin (Fig. 5B). However, consistent 
with expectations, the LCA60 antibody had no impact on infection with the MERS-
Uganda chimera, failing to neutralize the bat spike-expressing virus (Fig. 5B). We 
subsequently examined a second monoclonal antibody, G4, which had previously 
mapped to a conserved portion of the S2 region of the MERS-spike (Fig. 5A) (26). With 
the epitope relatively conserved in the MERS-Uganda spike, we tested the efficacy 
against the zoonotic spike chimera. However, the results demonstrate no neutralization 
of MERS-Uganda spike virus by the S2-targeted antibody (Fig. 5C). Notably, G4 also 
failed to neutralize wild-type MERS-CoV grown in the presence of exogenous trypsin 
(Fig. 5C). Together, the results indicate that both group 2C CoV spikes could escape 
neutralization by the S2-targeted antibody in the presence of exogenous trypsin. 
Overall, these experiments suggest that antibodies targeted against MERS-CoV, even to 
regions in the highly conserved S2 domain, may not have utility against viruses 
expressing the PDF-2180 spike.
Trypsin treatment rescues the replication of zoonotic HKU5-CoV. Based on the 
MERS-Uganda chimera virus, we wondered if a similar barrier prevented replication of 
other zoonotic CoVs. Previously, our group had generated a full-length infectious clone 
for HKU5-CoV, another group 2C coronavirus sequence isolated from bats. Similar to 
the MERS-Uganda chimera, the infectious clone of HKU5-CoV produced subgenomic 
transcripts but failed to achieve productive infection (6). Revisiting the full-length 
recombinant virus, we sought to determine if trypsin treatment could also rescue 
HKU5-CoV. Following HKU5-CoV infection, the addition of trypsin to the media resulted
FIG 6 Exogenous trypsin rescues replication of HKU5-CoV. Vero cells were infected with full-length HKU5-CoV in the presence or absence
of trypsin. (A) Expression (reverse transcription-quantitative PCR [qRT-PCR]) of HKU5-CoV viral genome in the presence or absence of
trypsin (n  3). (B) Immunoblotting of HKU5 spike protein and cellular actin 24 and 48 hours postinfection with various concentrations of
trypsin in the media. (C) Immunoblotting for MERS N protein and cellular actin following infection in the presence or absence of trypsin
and human DPP4 antibody. (D) Alignment of amino acid sequence from the S1/S2, endosomal cysteine protease (ECP), and the S2
cleavage sites. Green boxes represent key residues conserved, and red boxes outline amino acid changes that potentially impact cleavage.
in cytopathic effect and cell fusion. In contrast, cultures lacking trypsin showed no signs 
of viral infection. Exploring viral genomic RNA, trypsin in the culture media permitted 
robust infection with HKU5-CoV that increased over time and was absent in cells not 
treated with trypsin (Fig. 6A). Similarly, trypsin in the media also permitted the 
accumulation and proteolytic cleavage of the HKU5 spike protein in a dose- and 
time-dependent manner (Fig. 6B). Importantly, the addition of the anti-DPP4 antibody 
had no impact on HKU5-CoV infection, suggesting the use of a different receptor than 
that used by wild-type MERS-CoV, similar to the findings with the MERS-Uganda spike 
(Fig. 6C). Together, these results demonstrate that protease cleavage is also the primary 
barrier to infection of Vero cells with HKU5-CoV. Examining further, we compared the 
predicted cleavage at S1/S2 border, S2’, and the endosomal cysteine protease site 
across MERS, PDF2180, and HKU5 spikes (Fig. 6D) (26). For the S1/S2 site, MERS, Uganda, 
and HKU5 maintain the RXXR cleavage motif, although the different interior amino 
acids may alter efficiency. For the S2’ sequence, MERS and HKU5 also retain the RXXR 
motif; however, the Uganda spike lacks the first arginine (SNAR), potentially impacting
cleavage. Finally, all three spikes maintain an aromatic residue at position two in the 
endosomal cysteine protease (ECP) site (27). However, the HKU5 spike maintains N at 
position 1 which is similar to a MERS mutant previously shown to inactivate cathepsin 
L activation (28). Together, the results suggest that potential sequence changes in the 
protease cleavage sites may contribute to the trypsin dependency of MERS-Uganda and 
HKU5 spike-mediated infections.
DISCUSSION
In the manuscript, we expanded our examination of circulating zoonotic viruses and 
identified protease cleavage as an important barrier to emergence of some group 2C 
zoonotic CoVs. The chimeric virus containing the spike protein from PDF-2180 was 
capable of replication in Vero cells and human cells (Huh7 and Caco-2) if treated with 
exogenous trypsin. However, neither continuous nor primary human airway cultures 
were susceptible to infection, in contrast to wild-type MERS-CoV. The MERS-Uganda 
chimera also maintained replication despite treatment with antibodies blocking human 
DPP4, suggesting use of either an alternative receptor or a different entry mechanism 
for infection. Importantly, current therapeutics targeting the MERS spike protein 
showed no efficacy against the MERS-Uganda chimera, highlighting a potential public 
health vulnerability to this and related group 2C CoVs. Finally, the trypsin-mediated 
rescue of a second zoonotic group 2C CoV, HKU5-CoV, validates findings that sug-
gested that protease cleavage may represent a critical barrier to zoonotic CoV infection 
in new hosts (29, 30). Together, the results highlight the importance of spike processing 
in CoV infection, expand the correlates associated with emergence beyond receptor 
binding alone, and provide a platform strategy to recover previously noncultivatable 
zoonotic CoVs.
With the ongoing threat posed by circulating zoonotic viruses, understanding the 
barriers for viral emergence represents a critical area of research. For CoVs, receptor 
binding has been believed to be the primary constraint to infection in new host 
populations. Following the SARS-CoV outbreak, emergence in humans was attributed 
to mutations within the receptor-binding domain that distinguished the epidemic 
strain from progenitor viruses harbored in bats and civets (31). Yet, work by our group 
and others has indicated that zoonotic SARS-like viruses circulating in Southeast Asian 
bats are capable of infecting human cells by binding to the known human ACE2 
receptor without adaptation (13, 14, 32). Similarly, pseudotyped virus studies have 
identified zoonotic strains HKU4-CoV and NL140422-CoV as capable of binding to 
human DPP4 without mutations to the spike (30, 33). In this study, we demonstrate that 
both PDF-2180 and HKU5-CoV spikes are capable of binding to and infecting human 
cells if primed by trypsin cleavage. Together, the results argue that several circulating 
zoonotic CoV strains have the capacity to bind to human cells without adaption and 
that receptor binding may not be the only barrier to CoV emergence.
Data from this study implicate the processing of the spike protein as a critical factor 
for CoV infection. In the absence of trypsin, the MERS-Uganda and HKU5-CoV spikes 
were unable to mediate infection and initially suggested a lack of receptor compati-
bility (6, 16). However, exogenous trypsin treatment produced robust infection, indi-
cating that despite binding to human cells, CoVs cannot overcome incomplete spike 
processing. As such, evaluating zoonotic virus populations for emergence threats must 
also consider the capacity for CoV spike activation in addition to receptor binding. 
While exogenous processing of the spike has been well described as necessary for 
enteric CoVs (17), spike processing has not been considered a primary barrier for bat 
CoVs despite their enteric origins. In this new paradigm for bat CoVs, the combination 
of receptor binding and proteolytic activation by endogenous proteases permits 
zoonotic CoV infection, as with MERS-CoV and SARS-CoV (Fig. 7). The absence of 
receptor binding (Fig. 7A) or compatible host protease activity (Fig. 7B) restricts 
infection with certain zoonotic strains like PDF-2180 or HKU5-CoV. These barriers can be 
overcome with the addition of exogenous proteases, disrupting the need for host 
proteases and permitting receptor-dependent or receptor-independent entry (Fig. 7C).
FIG 7 Barriers to zoonotic coronavirus emergence. Both receptor binding and protease activitation are 
key correlates that govern zoonotic coronavirus emergence. (A) A lack of receptor binding with zoonotic 
CoVs precludes the infection of new host cells. (B) Despite receptor binding, the absence of compatible 
host proteases for spike cleavage restricts infection in new hosts. (C) The addition of exogenous protease 
overcomes the host protease barriers and may or may not require receptor binding.
Overall, the new paradigm argues that both receptor binding and protease activation 
barriers must be overcome for successful zoonotic CoV infection of a new host.
The requirement for exogenous trypsin treatment is not unique to MERS-Uganda or 
HKU5-CoV. Influenza strains are well known to require trypsin treatment to facilitate 
their release in cell culture (34). In addition, highly pathogenic avian influenza strains 
have been linked to mutations that improve cleavage by ubiquitous host protease, 
augmenting their tissue tropism and virulence (35). Similarly, a wealth of enteric viruses, 
including polio, cowpox, and rotaviruses, depend on trypsin to prime, modulate, and/or 
expand infection (36, 37). Even within the CoV family, enteric viruses, including porcine 
epidemic diarrhea virus (PEDV), porcine delta CoV, and swine acute diarrhea syndrome 
(SADS) CoV require trypsin for replication in vitro (38–40). Together, these prior studies 
illustrate the importance of protease activation in virus infections. However, the pro-
tease barrier to PDF-2180 and HKU5-CoV spike-mediated infection may also reflect on 
the emergence of SARS-CoV and MERS-CoV. While initial studies argued that receptor 
binding was the primary barrier, the existence of zoonotic strains capable of efficiently 
using the same human entry receptors contradicts that suggestion (13, 14). It is possible 
that emergence of epidemic CoV strains also requires modifying protease cleavage in 
either humans or an intermediate host, such as camels or civets, in addition to 
increased receptor-binding affinity. Consistent with this idea, reports have detailed 
differential infection with MERS-CoV based on host protease expression (20). Similarly, 
mouse adaptation of MERS-CoV resulted in spike modifications that alter protease 
activation and entry in vivo (41). Coupled with the augmented replication and protein 
production of wild-type MERS-CoV in the presence of trypsin, the results suggest that 
the proteolytic cleavage epidemic MER-CoV could still be enhanced, potentially by 
augmenting the cell surface entry mechanism, as previously described for SARS-CoV 
(42). While group 2B bat CoV strains (WIV1-CoV, WIV16-CoV, and SHC014-CoV) do not 
require trypsin for infection (9, 13, 14, 43), differences in protease activation may 
contribute to infection changes relative to the epidemic SARS-CoV. In this context, our 
findings expand the importance of protease cleavage as a criterion to consider for 
zoonotic virus emergence in a new host population.
In evaluating the threat to humans posed by PDF-2180 and HKU5-CoV, the results 
demonstrate a pathway to emergence. Neither CoV spike uses human DPP4 for entry, 
and the PDF-2180 chimera failed to replicate in human respiratory models, even in the 
presence of trypsin. As many different proteases can promote CoV entry, future studies
must determine if other protease treatments or other components can promote virus 
replication in HAE cultures (29, 44, 45). However, replication in Huh7 and Caco-2 cells 
indicates human infection compatibility and may portend differential tropism, possibly 
in the alimentary or biliary tracts, as has been described for several mammalian CoVs 
(38–40). MERS-Uganda or HKU5-CoV could utilize this same trypsin-rich environment in 
the gut to emerge as an enteric pathogen in humans, although its pathology and 
virulence would be hard to predict. Evidence from both SARS-CoV and MERS-CoV 
outbreaks suggests the involvement of enteric pathways during infection (46, 47). 
Replication in the gut might select for mutations that expand spike processing/tropism 
and allow replication in other tissues, including the lung, and lead to virulent disease 
in the new host population, as seen with porcine respiratory coronavirus (48). In 
examining the threat posed by PDF-2180 and HKU5-CoV, we must consider the 
emergence of these CoVs in tissues other than the lung and that they harbor distinct 
pathologies compared with epidemic SARS and MERS-CoV.
The receptor dynamics of MERS-Uganda and HKU5-CoV also remain unclear in the 
context of this study. In the presence of trypsin, neither spike protein requires the 
MERS-CoV receptor DPP4 for entry, which is consistent with the differences between 
the receptor-binding domains of the bat and epidemic strains. Therefore, it was not 
surprising that antibodies that target the RBD of the MERS-CoV spike were ineffective 
in blocking infection of the PDF-2180 chimera. However, the S2-targeted antibody G4 
also had no efficacy against MERS-Uganda, despite a relatively conserved binding 
epitope. This result is possibly explained by differing amino acid sequences between 
MERS-CoV and PDF-2180 at the G4 epitope, specifically residue 1175, which is associ-
ated with G4 escape mutants in MERS-CoV (49). Alternatively, the G4 antibody also 
failed to neutralize wild-type MERS-CoV grown in the presence of trypsin, indicating 
that entry is still possible, despite treatment with antibody binding the S2 domain. 
These results suggest that trypsin treatment may permit a conformational change 
either masking the G4 epitope or facilitating fusion/entry prior to antibody binding. 
Conversely, the presence of trypsin may prime a receptor-independent entry for the 
MERS-Uganda chimera, similar to the JHVM strain of MHV (50). Yet, this result would 
contrast with that of PEDV, which requires receptor binding prior to trypsin activation 
to facilitate infection (39). Importantly, the lack of infection in respiratory cells suggests 
that some receptor or attachment factor is necessary to mediate entry with the 
PDF-2180 spike. Recent work with MERS-CoV binding sialic acid supports this idea (51) 
and indicates that the PDF-2180 spike may not have a similar binding motif. Overall, 
further experimental studies are required to fully understand the receptor dynamics of 
the PDF-2180 spike.
While providing a new strategy to recover zoonotic CoVs, the manuscript highlights 
proteolytic cleavage of the spike as a major barrier to group 2C zoonotic CoV infection. 
For both MERS-Uganda and HKU5-CoV, the addition of exogenous trypsin rescues 
infection, indicating that spike cleavage, not receptor binding, limits these strains in 
new hosts and tissues. The adaptation of the protease cleavage sites or infection of 
tissues with robust host protease expression could permit these two zoonotic CoV 
strains to emerge and may pose a threat to public health due to the absence of 
effective spike-based therapeutics. In considering cross-species transmission, our re-
sults using reconstructed bat group 2C CoVs confirm spike processing as a correlate 
associated with emergence. Adding spike processing to receptor binding as primary 
barriers offers a new framework to evaluate the threat of emergence for zoonotic CoV 
strains.
MATERIALS AND METHODS
Cells, viruses, in vitro infection, and plaque assays. Vero cells were grown in Dulbecco’s modified 
Eagle medium (DMEM; Gibco, CA) supplemented with 5% FetalClone II (HyClone, UT) and antibiotic/
antimycotic (anti/anti) (Gibco). Huh7 cells were grown in DMEM supplemented with 10% FetalClone II 
and anti/anti. Caco-2 cells were grown in MEM (Gibco) supplemented with 20% fetal bovine serum 
(HyClone) and anti/anti. Human airway epithelial cell (HAE) cultures were obtained from the University 
of North Carolina (UNC) Cystic Fibrosis (CF) Center Tissue Procurement and Cell Culture Core from human
lungs procured under University of North Carolina at Chapel Hill Institutional Review Board-approved 
protocols. Wild-type MERS-CoV, chimeric MERS-Uganda, and HKU5-CoV were cultured on Vero cells in 
Opti-MEM (Gibco) supplemented with anti/anti. For indicated experiments, trypsin (Gibco) was added at 
0.5 g/ml unless otherwise indicated.
Generation of wild-type MERS-CoV, MERS-Uganda, and HKU5-CoV viruses utilized reverse genetics 
and have been previously described (6, 16, 19). For MERS-Uganda chimera expressing RFP, we utilized the 
MERS-CoV backbone, replacing ORF5 with RFP as previously described (19). Synthetic constructions of 
chimeric mutant and full-length MERS-Uganda and HKU5-CoV were approved by the University of North 
Carolina Institutional Biosafety Committee.
Replication in Vero, Calu-3 2B4, Caco-2, Huh7, and HAE cells was performed as previously described 
(12, 52–54). Briefly, cells were washed with PBS and inoculated with virus or mock diluted in Opti-MEM 
for 60 minutes at 37°C. Following inoculation, cells were washed three times, and fresh medium with or 
without trypsin was added to signify time zero. Three or more biological replicates were harvested at 
each described time point. For HAE cultures, apical surfaces were washed with PBS containing 5 g/ml 
trypsin at 0, 8, 18, 24, and 48 hours postinfection. Sample collections were not conducted in a blind 
manner nor were samples randomized. Microscopy photos were captured via a Keyence BZ-X700 
microscope.
For antibody neutralization assays, MERS-CoV and MERS-Uganda stocks were grown in Opti-MEM 
both with and without trypsin. All stocks were quantified via plaque assay by overlaying cells with 0.8%
agarose in Opti-MEM supplemented with 0.5 g/ml trypsin and anti/anti. MERS-Uganda stocks grown 
without trypsin had low titers but were sufficient for neutralization assays.
For anti-DPP4 blocking experiments, Vero cells were preincubated with serum-free Opti-MEM 
containing 5 g/ml anti-human DPP4 antibody (R&D systems, MN) for 1 hour. Medium was removed, and 
cells were infected for 1 hour with virus or mock inoculum at a multiplicity of infection of 0.1. The 
inoculum was removed, cells were washed three times with PBS, and medium was replaced.
RNA isolation and quantification. RNA was isolated via TRIzol reagent (Invitrogen, CA) and 
Direct-zol RNA miniprep kit (Zymo Research, CA) according to the manufacturer’s protocol. MERS-CoV 
and MERS-Uganda genomic RNA (gRNA) was quantified via TaqMan fast virus 1-step master mix (Applied 
Biosystems, CA) using previously reported primers and probes targeting ORF1ab (54) and normalized to 
host 18S rRNA (Applied Biosystems). HKU5-CoV RNA was first reverse transcribed using SuperScript III 
(Invitrogen) and was then assayed using SsoFast EvaGreen supermix (Bio-Rad, CA) and scaled to host 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) transcript levels. HKU5 gRNA was amplified with 
the following primers: forward, 5=-CTCTCTCTCGTTCTCTTGCAGAAC-3=; and reverse, 5=-GTTGAGCTCTGCT 
CTATACTTGCC-3=. GAPDH RNA was amplified with the following primers: forward, 5=-AGCCACATCGCT 
GAGACA-3=; and reverse, 5=-GCCCAATACGACCAAATCC-3=. Fold change was calculated using the 
threshold cycle (ΔΔCT) method and was scaled to RNA present at 0 hours postinfection.
Generation of VRP, polyclonal mouse antisera, and Western blot analysis. Virus replicon particles 
(VRPs) expressing the MERS-CoV nucleocapsid, MERS-Uganda spike, or HKU5-5 CoV spike were con-
structed using a non-select agent biosafety level 2 (BSL2) Venezuelan equine encephalitis virus (VEEV) 
strain 3546 replicon system, as previously described (55). Briefly, RNA containing the nonstructural genes 
of VEEV and either MERS-CoV nucleocapsid or HKU5-5 CoV spike was packaged using helper RNAs 
encoding VEEV structural proteins as described previously (56). Six-week-old female BALB/c mice were 
primed and boosted with VRPs to generate mouse antisera toward either MERS-CoV nucleocapsid or 
HKU5-5 CoV spike. Following vaccination, mouse polyclonal sera were collected as described previously 
(57). For Western blotting, lysates from infected cells were prepared as described before in detail (58), 
and these blots were probed using the indicated mouse polyclonal sera. MERS-CoV N sera was able to 
detect to HKU5-CoV N protein via Western blot as previously described (7).
Virus neutralization assays. Plaque reduction neutralization titer assays were performed with 
previously characterized antibodies against MERS-CoV, as previously described (25, 49). Briefly, antibod-
ies were serially diluted 6- to 8-fold and incubated with 80 PFU of the indicated viruses for 1 h at  37°C. 
The virus and antibodies were then added to a 6-well plate of confluent Vero cells in triplicate. After a 
1 hour incubation at 37°C, cells were overlaid with 3 ml of 0.8% agarose in Opti-MEM supplemented with 
0.5 g/ml trypsin and anti/anti. Plates were incubated for 2 or 3 days at 37°C for MERS-CoV or MERS-
Uganda, respectively, and were then stained with neutral red for 3 h, and plaques were counted. The 
percentage of plaque reduction was calculated as (1 – [number of plaques with antibody/number of 
plaques without antibody])  100.
Biosafety and biosecurity. Reported studies were initiated after the University of North Carolina 
Institutional Biosafety Committee approved the experimental protocols. All work for these studies was 
performed with approved standard operating procedures (SOPs) and safety conditions for MERS-CoV and 
other related CoVs. Our institutional CoV BSL3 facilities have been designed to conform to the safety 
requirements recommended by Biosafety in Microbiological and Biomedical Laboratories (BMBL), the U.S. 
Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and 
Prevention (CDC), and the National Institutes of Health (NIH). Laboratory safety plans have been 
submitted, and the facility has been approved for use by the UNC Department of Environmental Health 
and Safety (EHS) and the CDC.
Accession number(s). The nearly complete genome sequence for MERS-CoV EMC (GenBank acces-
sion number JX869059) and PREDICT/PDF-2180 (GenBank accession number KX574227) were previously 
deposited in GenBank (16, 59).
1. Reperant LA, Osterhaus A. 2017. AIDS, avian flu, SARS, MERS, Ebola,
Zika . . . what next? Vaccine 35:4470 – 4474. https://doi.org/10.1016/j
.vaccine.2017.04.082.
2. Perlman S, Netland J. 2009. Coronaviruses post-SARS: update on repli-
cation and pathogenesis. Nat Rev Microbiol 7:439 – 450. https://doi.org/
10.1038/nrmicro2147.
3. Morse SS, Mazet JA, Woolhouse M, Parrish CR, Carroll D, Karesh WB,
Zambrana-Torrelio C, Lipkin WI, Daszak P. 2012. Prediction and preven-
tion of the next pandemic zoonosis. Lancet 380:1956 –1965. https://doi
.org/10.1016/S0140-6736(12)61684-5.
4. Cunningham AA, Daszak P, Wood JLN. 2017. One Health, emerging
infectious diseases and wildlife: two decades of progress? Philos Trans R
Soc Lond B Biol Sci 372:20160167. https://doi.org/10.1098/rstb.2016
.0167.
5. Chafekar A, Fielding BC. 2018. MERS-CoV: understanding the latest
human coronavirus threat. Viruses 10:E93. https://doi.org/10.3390/
v10020093.
6. Agnihothram S, Yount BL, Jr., Donaldson EF, Huynh J, Menachery VD,
Gralinski LE, Graham RL, Becker MM, Tomar S, Scobey TD, Osswald HL,
Whitmore A, Gopal R, Ghosh AK, Mesecar A, Zambon M, Heise M,
Denison MR, Baric RS. 2014. A mouse model for Betacoronavirus sub-
group 2c using a bat coronavirus strain HKU5 variant. mBio 5:e00047-14.
https://doi.org/10.1128/mBio.00047-14.
7. Agnihothram S, Gopal R, Yount BL, Jr., Donaldson EF, Menachery VD,
Graham RL, Scobey TD, Gralinski LE, Denison MR, Zambon M, Baric RS.
2014. Evaluation of serologic and antigenic relationships between mid-
dle eastern respiratory syndrome coronavirus and other coronaviruses
to develop vaccine platforms for the rapid response to emerging coro-
naviruses. J Infect Dis 209:995–1006. https://doi.org/10.1093/infdis/
jit609.
8. Johnson BA, Graham RL, Menachery VD. 2018. Viral metagenomics,
protein structure, and reverse genetics: key strategies for investigating
coronaviruses. Virology 517:30 –37. https://doi.org/10.1016/j.virol.2017
.12.009.
9. Becker MM, Graham RL, Donaldson EF, Rockx B, Sims AC, Sheahan T,
Pickles RJ, Corti D, Johnston RE, Baric RS, Denison MR. 2008. Synthetic
recombinant bat SARS-like coronavirus is infectious in cultured cells and
in mice. Proc Natl Acad Sci U S A 105:19944 –19949. https://doi.org/10
.1073/pnas.0808116105.
10. Rockx B, Baas T, Zornetzer GA, Haagmans B, Sheahan T, Frieman M, Dyer
MD, Teal TH, Proll S, van den Brand J, Baric R, Katze MG. 2009. Early
upregulation of acute respiratory distress syndrome-associated cyto-
kines promotes lethal disease in an aged-mouse model of severe acute
respiratory syndrome coronavirus infection. J Virol 83:7062–7074.
https://doi.org/10.1128/JVI.00127-09.
11. Sheahan T, Rockx B, Donaldson E, Sims A, Pickles R, Corti D, Baric R. 2008.
Mechanisms of zoonotic severe acute respiratory syndrome coronavirus
host range expansion in human airway epithelium. J Virol 82:2274 –2285.
https://doi.org/10.1128/JVI.02041-07.
12. Sheahan T, Rockx B, Donaldson E, Corti D, Baric R. 2008. Pathways of
cross-species transmission of synthetically reconstructed zoonotic se-
vere acute respiratory syndrome coronavirus. J Virol 82:8721– 8732.
https://doi.org/10.1128/JVI.00818-08.
13. Menachery VD, Yount BL, Jr., Sims AC, Debbink K, Agnihothram SS,
Gralinski LE, Graham RL, Scobey T, Plante JA, Royal SR, Swanstrom J,
Sheahan TP, Pickles RJ, Corti D, Randell SH, Lanzavecchia A, Marasco WA,
Baric RS. 2016. SARS-like WIV1-CoV poised for human emergence. Proc
Natl Acad Sci U S A 113:3048 –3053. https://doi.org/10.1073/pnas
.1517719113.
14. Menachery VD, Yount BL, Jr., Debbink K, Agnihothram S, Gralinski LE,
Plante JA, Graham RL, Scobey T, Ge XY, Donaldson EF, Randell SH,
Lanzavecchia A, Marasco WA, Shi ZL, Baric RS. 2015. A SARS-like cluster
of circulating bat coronaviruses shows potential for human emergence.
Nat Med 21:1508 –1513. https://doi.org/10.1038/nm.3985.
15. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB,
Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Mo
C, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan
R, Denison MR, Baric RS. 2017. Broad-spectrum antiviral GS-5734 inhibits
both epidemic and zoonotic coronaviruses. Sci Transl Med 9:eaal3653.
https://doi.org/10.1126/scitranslmed.aal3653.
16. Anthony SJ, Gilardi K, Menachery VD, Goldstein T, Ssebide B, Mbabazi R,
Navarrete-Macias I, Liang E, Wells H, Hicks A, Petrosov A, Byarugaba DK,
Debbink K, Dinnon KH, Scobey T, Randell SH, Yount BL, Cranfield M,
Johnson CK, Baric RS, Lipkin WI, Mazet JA. 2017. Further evidence for
bats as the evolutionary source of Middle East respiratory syndrome
coronavirus. mBio 8:e00373-17. https://doi.org/10.1128/mBio.00373-17.
17. Hofmann M, Wyler R. 1988. Propagation of the virus of porcine epidemic
diarrhea in cell culture. J Clin Microbiol 26:2235–2239.
18. Menachery VD, Dinnon KH III, Yount BL, Jr., McAnarney ET, Gralinski LE,
Hale A, Graham RL, Scobey T, Anthony SJ, Wang L, Graham B, Randell SH,
Lipkin WI, Baric RS. 2019. Trypsin treatment unlocks barrier for zoonotic
coronaviruses infection. bioRxiv https://doi.org/10.1101/768663.
19. Scobey T, Yount BL, Sims AC, Donaldson EF, Agnihothram SS, Menachery
VD, Graham RL, Swanstrom J, Bove PF, Kim JD, Grego S, Randell SH, Baric
RS. 2013. Reverse genetics with a full-length infectious cDNA of the
Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci U S A
110:16157–16162. https://doi.org/10.1073/pnas.1311542110.
20. Park J-E, Li K, Barlan A, Fehr AR, Perlman S, McCray PB, Jr., Gallagher T.
2016. Proteolytic processing of Middle East respiratory syndrome coro-
navirus spikes expands virus tropism. Proc Natl Acad Sci U S A 113:
12262–12267. https://doi.org/10.1073/pnas.1608147113.
21. de Wilde AH, Raj VS, Oudshoorn D, Bestebroer TM, van Nieuwkoop S,
Limpens RWAL, Posthuma CC, van der Meer Y, Bárcena M, Haagmans BL,
Snijder EJ, van den Hoogen BG. 2013. MERS-coronavirus replication
induces severe in vitro cytopathology and is strongly inhibited by
cyclosporin A or interferon-alpha treatment. J Gen Virol 94:1749 –1760.
https://doi.org/10.1099/vir.0.052910-0.
22. Banach BS, Orenstein JM, Fox LM, Randell SH, Rowley AH, Baker SC. 2009.
Human airway epithelial cell culture to identify new respiratory viruses:
coronavirus NL63 as a model. J Virol Methods 156:19 –26. https://doi
.org/10.1016/j.jviromet.2008.10.022.
23. Tekes G, Thiel HJ. 2016. Feline coronaviruses: pathogenesis of feline
infectious peritonitis. Adv Virus Res 96:193–218. https://doi.org/10.1016/
bs.aivir.2016.08.002.
24. Song D, Park B. 2012. Porcine epidemic diarrhoea virus: a comprehensive
review of molecular epidemiology, diagnosis, and vaccines. Virus Genes
44:167–175. https://doi.org/10.1007/s11262-012-0713-1.
25. Corti D, Zhao J, Pedotti M, Simonelli L, Agnihothram S, Fett C,
ACKNOWLEDGMENTS
The research described in this work was supported by grants from the United States 
Agency for International Development (USAID) Emerging Pandemic Threats PREDICT 
project (cooperative agreement number GHN-A-OO-09-00010-00) and from the Na-
tional Institute of Allergy and Infectious Disease and the National Institute of Aging of 
the NIH under awards U19AI109761 and AI110700 to R.S.B. and R00AG049092 to V.D.M. 
HAE cultures were supported by the National Institute of Diabetes and Digestive and 
Kidney Disease under award NIH DK065988 to S.H.R.
Trypsin-resistant Vero cells were kindly provided by Linda Saif. Monoclonal antibody 
LCA60 was provided by Davide Corti and Humabs Biomed SA.
The content described herein is solely the responsibility of the authors and does not 
necessarily represent the official views of the NIH.
REFERENCES
Fernandez-Rodriguez B, Foglierini M, Agatic G, Vanzetta F, Gopal R,
Langrish CJ, Barrett NA, Sallusto F, Baric RS, Varani L, Zambon M, Perlman
S, Lanzavecchia A. 2015. Prophylactic and postexposure efficacy of a
potent human monoclonal antibody against MERS coronavirus. Proc
Natl Acad Sci U S A 112:10473–10478. https://doi.org/10.1073/pnas
.1510199112.
26. Kleine-Weber H, Elzayat MT, Hoffmann M, Pöhlmann S. 2018. Functional
analysis of potential cleavage sites in the MERS-coronavirus spike pro-
tein. Sci Rep 8:16597. https://doi.org/10.1038/s41598-018-34859-w.
27. Biniossek ML, Nagler DK, Becker-Pauly C, Schilling O. 2011. Proteomic
identification of protease cleavage sites characterizes prime and non-
prime specificity of cysteine cathepsins B, L, and S. J Proteome Res
10:5363–5373. https://doi.org/10.1021/pr200621z.
28. Yang Y, Liu C, Du L, Jiang S, Shi Z, Baric RS, Li F. 2015. Two mutations
were critical for bat-to-human transmission of Middle East respiratory
syndrome coronavirus. J Virol 89:9119 –9123. https://doi.org/10.1128/JVI
.01279-15.
29. Zheng Y, Shang J, Yang Y, Liu C, Wan Y, Geng Q, Wang M, Baric R, Li F,
Zheng Y, Shang J, Yang Y, Liu C, Wan Y, Geng Q, Wang M, Baric R, Li F.
2018. Lysosomal proteases are a determinant of coronavirus tropism. J
Virol 92:e01504-18. https://doi.org/10.1128/JVI.01504-18.
30. Yang Y, Du L, Liu C, Wang L, Ma C, Tang J, Baric RS, Jiang S, Li F. 2014.
Receptor usage and cell entry of bat coronavirus HKU4 provide insight
into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci
U S A 111:12516 –12521. https://doi.org/10.1073/pnas.1405889111.
31. Graham RL, Baric RS. 2010. Recombination, reservoirs, and the modular
spike: mechanisms of coronavirus cross-species transmission. J Virol
84:3134 –3146. https://doi.org/10.1128/JVI.01394-09.
32. Ge X-Y, Li J-L, Yang X-L, Chmura AA, Zhu G, Epstein JH, Mazet JK, Hu B,
Zhang W, Peng C, Zhang Y-J, Luo C-M, Tan B, Wang N, Zhu Y, Crameri G,
Zhang S-Y, Wang L-F, Daszak P, Shi Z-L. 2013. Isolation and character-
ization of a bat SARS-like coronavirus that uses the ACE2 receptor.
Nature 503:535–538. https://doi.org/10.1038/nature12711.
33. Luo C-M, Wang N, Yang X-L, Liu H-Z, Zhang W, Li B, Hu B, Peng C, Geng
Q-B, Zhu G-J, Li F, Shi Z-L, Luo C-M, Wang N, Yang X-L, Liu H-Z, Zhang
W, Li B, Hu B, Peng C, Geng Q-B, Zhu G-J, Li F, Shi Z-L. 2018. Discovery
of novel bat coronaviruses in South China that use the same receptor as
Middle East respiratory syndrome coronavirus. J Virol 92:e00116-18.
https://doi.org/10.1128/JVI.00116-18.
34. Klenk H-D, Rott R, Orlich M, Blödorn J. 1975. Activation of influenza A
viruses by trypsin treatment. Virology 68:426 – 439. https://doi.org/10
.1016/0042-6822(75)90284-6.
35. Luczo JM, Stambas J, Durr PA, Michalski WP, Bingham J. 2015. Molecular
pathogenesis of H5 highly pathogenic avian influenza: the role of the
haemagglutinin cleavage site motif. Rev Med Virol 25:406 – 430. https://
doi.org/10.1002/rmv.1846.
36. Clark SM, Roth JR, Clark ML, Barnett BB, Spendlove RS. 1981. Trypsin
enhancement of rotavirus infectivity: mechanism of enhancement. J
Virol 39:816 – 822.
37. Roivainen M, Hovi T. 1987. Intestinal trypsin can significantly modify
antigenic properties of polioviruses: implications for the use of inacti-
vated poliovirus vaccine. J Virol 61:3749 –3753.
38. Hu H, Jung K, Vlasova AN, Chepngeno J, Lu Z, Wang Q, Saif LJ. 2015.
Isolation and characterization of porcine deltacoronavirus from pigs
with diarrhea in the United States. J Clin Microbiol 53:1537–1548.
https://doi.org/10.1128/JCM.00031-15.
39. Wicht O, Li W, Willems L, Meuleman TJ, Wubbolts RW, van Kuppeveld FJ,
Rottier PJ, Bosch BJ. 2014. Proteolytic activation of the porcine epidemic
diarrhea coronavirus spike fusion protein by trypsin in cell culture. J Virol
88:7952–7961. https://doi.org/10.1128/JVI.00297-14.
40. Zhou P, Fan H, Lan T, Yang X-L, Shi W-F, Zhang W, Zhu Y, Zhang Y-W, Xie
Q-M, Mani S, Zheng X-S, Li B, Li J-M, Guo H, Pei G-Q, An X-P, Chen J-W,
Zhou L, Mai K-J, Wu ZX, Li D, Anderson DE, Zhang L-B, Li S-Y, Mi Z-Q, He
T-T, Cong F, Guo P-J, Huang R, Luo Y, Liu X-L, Chen J, Huang Y, Sun Q,
Zhang X-L-L, Wang Y-Y, Xing S-Z, Chen Y-S, Sun Y, Li J, Daszak P, Wang
L-F, Shi Z-L, Tong Y-G, Ma J-Y. 2018. Fatal swine acute diarrhoea syn-
drome caused by an HKU2-related coronavirus of bat origin. Nature
556:255–258. https://doi.org/10.1038/s41586-018-0010-9.
41. Li K, Wohlford-Lenane CL, Channappanavar R, Park J-E, Earnest JT, Bair
TB, Bates AM, Brogden KA, Flaherty HA, Gallagher T, Meyerholz DK,
Perlman S, McCray PB, Jr. 2017. Mouse-adapted MERS coronavirus
causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad
Sci U S A 114:E3119 –E3128. https://doi.org/10.1073/pnas.1619109114.
42. Matsuyama S, Ujike M, Morikawa S, Tashiro M, Taguchi F. 2005. Protease-
mediated enhancement of severe acute respiratory syndrome corona-
virus infection. Proc Natl Acad Sci U S A 102:12543–12547. https://doi
.org/10.1073/pnas.0503203102.
43. Zeng L-P, Gao Y-T, Ge X-Y, Zhang Q, Peng C, Yang X-L, Tan B, Chen J,
Chmura AA, Daszak P, Shi Z-L. 2016. Bat severe acute respiratory
syndrome-like coronavirus WIV1 encodes an extra accessory protein,
ORFX, involved in modulation of the host immune response. J Virol
90:6573– 6582. https://doi.org/10.1128/JVI.03079-15.
44. Millet JK, Whittaker GR. 2015. Host cell proteases: critical determinants of
coronavirus tropism and pathogenesis. Virus Res 202:120 –134. https://
doi.org/10.1016/j.virusres.2014.11.021.
45. Earnest JT, Hantak MP, Li K, McCray PB, Jr., Perlman S, Gallagher T. 2017.
The tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding
host cell receptors and proteases. PLoS Pathog 13:e1006546. https://doi
.org/10.1371/journal.ppat.1006546.
46. Zhou J, Li C, Zhao G, Chu H, Wang D, Yan HH, Poon VK, Wen L, Wong
BH-Y, Zhao X, Chiu MC, Yang D, Wang Y, Au-Yeung RKH, Chan IH-Y, Sun
S, Chan JF-W, To KK-W, Memish ZA, Corman VM, Drosten C, Hung IF-N,
Zhou Y, Leung SY, Yuen K-Y. 2017. Human intestinal tract serves as an
alternative infection route for Middle East respiratory syndrome corona-
virus. Sci Adv 3:eaao4966. https://doi.org/10.1126/sciadv.aao4966.
47. Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J, Wang H, Shen H, Qiu L,
Li Z, Geng J, Cai J, Han H, Li X, Kang W, Weng D, Liang P, Jiang S. 2004.
Organ distribution of severe acute respiratory syndrome (SARS) associ-
ated coronavirus (SARS-CoV) in SARS patients: implications for patho-
genesis and virus transmission pathways. J Pathol 203:622– 630. https://
doi.org/10.1002/path.1560.
48. Zhang X, Hasoksuz M, Spiro D, Halpin R, Wang S, Stollar S, Janies D,
Hadya N, Tang Y, Ghedin E, Saif L. 2007. Complete genomic sequences,
a key residue in the spike protein and deletions in nonstructural protein
3b of US strains of the virulent and attenuated coronaviruses, transmis-
sible gastroenteritis virus and porcine respiratory coronavirus. Virology
358:424 – 435. https://doi.org/10.1016/j.virol.2006.08.051.
49. Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL,
Cottrell CA, Becker MM, Wang L, Shi W, Kong W-P, Andres EL, Kettenbach
AN, Denison MR, Chappell JD, Graham BS, Ward AB, McLellan JS. 2017.
Immunogenicity and structures of a rationally designed prefusion MERS-
CoV spike antigen. Proc Natl Acad Sci U S A 114:E7348 –E7357. https://
doi.org/10.1073/pnas.1707304114.
50. Gallagher TM, Buchmeier MJ, Perlman S. 1992. Cell receptor-independent
infection by a neurotropic murine coronavirus. Virology 191:517–522.
https://doi.org/10.1016/0042-6822(92)90223-c.
51. Li W, Hulswit RJG, Widjaja I, Raj VS, McBride R, Peng W, Widagdo W,
Tortorici MA, van Dieren B, Lang Y, van Lent JWM, Paulson JC, de Haan
CAM, de Groot RJ, van Kuppeveld FJM, Haagmans BL, Bosch B-J. 2017.
Identification of sialic acid-binding function for the Middle East respira-
tory syndrome coronavirus spike glycoprotein. Proc Natl Acad Sci U S A
114:E8508 –E8517. https://doi.org/10.1073/pnas.1712592114.
52. Sims AC, Tilton SC, Menachery VD, Gralinski LE, Schafer A, Matzke MM,
Webb-Robertson B-J, Chang J, Luna ML, Long CE, Shukla AK, Bankhead
AR, III, Burkett SE, Zornetzer G, Tseng C-TK, Metz TO, Pickles R, Mc-
Weeney S, Smith RD, Katze MG, Waters KM, Baric RS. 2013. Release of
severe acute respiratory syndrome coronavirus nuclear import block
enhances host transcription in human lung cells. J Virol 87:3885–3902.
https://doi.org/10.1128/JVI.02520-12.
53. Sims AC, Burkett SE, Yount B, Pickles RJ. 2008. SARS-CoV replication and
pathogenesis in an in vitro model of the human conducting airway
epithelium. Virus Res 133:33– 44. https://doi.org/10.1016/j.virusres.2007
.03.013.
54. Almazán F, DeDiego ML, Sola I, Zuñiga S, Nieto-Torres JL, Marquez-
Jurado S, Andrés G, Enjuanes L. 2013. Engineering a replication-
competent, propagation-defective Middle East respiratory syndrome
coronavirus as a vaccine candidate. mBio 4:e00650-13. https://doi.org/
10.1128/mBio.00650-13.
55. Agnihothram S, Menachery VD, Yount BL, Lindesmith LC, Scobey T,
Whitmore A, Schafer A, Heise MT, Baric RS. 2018. Development of a
broadly accessible Venezuelan equine encephalitis virus replicon parti-
cle vaccine platform. J Virol 92:e00027-18. https://doi.org/10.1128/JVI
.00027-18.
56. Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M,
Funkhouser W, Gralinski L, Totura A, Heise M, Baric RS. 2011. A double-
inactivated severe acute respiratory syndrome coronavirus vaccine pro-
vides incomplete protection in mice and induces increased eosinophilic
proinflammatory pulmonary response upon challenge. J Virol 85:
12201–12215. https://doi.org/10.1128/JVI.06048-11.
57. Sheahan T, Whitmore A, Long K, Ferris M, Rockx B, Funkhouser W,
Donaldson E, Gralinski L, Collier M, Heise M, Davis N, Johnston R, Baric
RS. 2011. Successful vaccination strategies that protect aged mice from
lethal challenge from influenza virus and heterologous severe acute
respiratory syndrome coronavirus. J Virol 85:217–230. https://doi.org/10
.1128/JVI.01805-10.
58. Huynh J, Li S, Yount B, Smith A, Sturges L, Olsen JC, Nagel J, Johnson JB,
Agnihothram S, Gates JE, Frieman MB, Baric RS, Donaldson EF. 2012.
Evidence supporting a zoonotic origin of human coronavirus strain
NL63. J Virol 86:12816 –12825. https://doi.org/10.1128/JVI.00906-12.
59. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA.
2012. Isolation of a novel coronavirus from a man with pneumonia in
Saudi Arabia. N Engl J Med 367:1814 –1820. https://doi.org/10.1056/
NEJMoa1211721.
